Stay updated with breaking news from Hetero healthcare. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The government on Tuesday waived customs duty on a key coronavirus (Covid-19) drug Remdesivir and its raw materials to lower cost amid a sharp increase in demand in the country. According to a notification from the customs department, the duty waiver was for Remdesivir injection, Remdesivir API and Beta Cyclodextrin, a key input, till October 31, 2021. Commerce and Industry Minister Piyush Goyal in a statement said, “In line with Prime Minister Narendra Modi’s priority to ensure affordable medical care for Covid-19 patients, imports of Remdesivir API, injection and specific inputs have been made import duty free. This should increase supply and reduce cost thus providing relief to patients.
Hyderabad: Three arrested for black marketing Remdesivir drug By Yunus Y Lasania| Updated: 19th April 2021 9:38 pm IST Representational image. Hyderabad: Three persons, including two employees of Hetero Healthcare, were arrested by the city police for black marketing generic versions of the Remdesivir drug (vials), which is currently in high demand to treat COVID-19 patients. The accused were selling each vial of the drug for as much as Rs 20,000 to those who are desperately looking to purchase it. Twelve Remdesivir 100 mg injections were recovered from their possession. According to the deputy commissioner of police (north zone), the accused were identified as Shaik Saleem Jaffar, B. Venkatesh and Jonnala Sharan Sai. Of them, Saleem and Venkatesh are employed with Hetero Health , Kukatpally, as a area business manager and filed sales officer. The third accused and their accomplice, Sharan, is an employee of Alkem Pharmacy. All three of them were arrested near the Hyderabad Public School, Begumpet, on Monday.
Government aims to double production of Remdesivir injection in 15 days, says Mandaviya April 18, 2021 Mansukh Mandaviya (File photo) - KUMAR SS× 20 plants to be added to double output to 3 lakh vials daily: Minister The government is trying to double the production of Remdesivir injection, used in the treatment of Covid-19 infected patients, in the next 15 days, Mansukh Mandaviya, Minister of State for Chemicals and Fertilisers, said on Sunday. The announcement follows a decision by seven pharmaceutical companies in India to reduce the price of the lifesaving drug by 25-70 per cent. Sharing a video message on Twitter, Mandaviya said, “Government is trying to ramp up the production of lifesaving Remdesivir injection in the country and to make it more affordable. Production will be doubled to 3 lakh vials from the current production of 1.5 lakh vials each day.”
Not Price Caps But By Increasing Production: How Centre Is Addressing Remdesivir Shortage swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.
Remdesivir price slashed by 25-70% Our Bureaus New Delhi/Hyderabad/Bengaluru | Updated on April 17, 2021 × As reports of shortages and black-marketing of antiviral Remdesivir come in from across the country, the Centre intervened to make the injectable more affordable for patients. Seven companies licensed to make the drug in India have “voluntarily lowered” their prices per 100mg/vial, in the range of 25-70 per cent. The companies include Cadila Healthcare, Syngene International, Dr Reddy’s Laboratories, Cipla, Mylan, Jubilant Generics and Hetero Healthcare, a note from the National Pharmaceutical Pricing Authority said. States crack down This, even as Andhra Pradesh cracked the whip and capped Remdesivir price at ₹2,500 for 100mg; Karnataka threatened action against black-marketeers, and Maharashtra started a toll-free number for patients needing the drug.
Hepatitis Therapeutics Market: Public Concerns of Morbidity and Mortality and Burden on Healthcare Systems of Hepatitis steers Growth, Market projected to expand at 2.3% CAGR from 2018 - 2026, TMR - Rising penetration of global players to make Asia Pacific prominent region in the near future ALBANY, N.Y., March 16, 2021 /PRNewswire/ -- Most commonly caused by a group of viruses known as the hepatitis viruses, hepatitis is an inflammation of the liver that can cause a number of health problems and can even lead to death. There are five main strains of the hepatitis virus, namely type A, B, C, D, and E. While all strains of hepatitis viruses causes liver disease, each type of virus strain is related to different severity of the illness. In particular, type B and type C are related to chronic diseases of the liver, cancer and viral hepatitis-related fatalities. According to statistics published by the World Health Organization, hepatitis B and/or C is prevalent in approximately 325 million people worldwide, and for most testing and treatment is beyond reach.
niravFebruary 19, 2021 Coherent Market Insights report on the global Betaxolol Market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators for the said market during the forecast period from 2020 to 2027. The report provides the overall market value of the global Betaxolol Market for the period of 2020 to 2027, with 2019 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global Betaxolol Market for the forecast period. The report has been prepared after an extensive primary and secondary research. Primary research involves bulk of research efforts, wherein analysts carry out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global Betaxolol Market.
(MENAFN - Coherent Market Insights) High prevalence of hepatitis is expected to propel growth of the global hepatitis drugs market. For instance, in May 2019, according to the study, âPrevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwandaâ, published in May 2019, in BMC Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in the study population. Moreover, development of novel diagnostic tests is also expected to aid in growth of the market. For instance, in January 2019, LabCorp, along with its subsidiary Covance Inc., partnered with GENFIT, a biopharmaceutical company focused on R&D in liver diseases, for access to non-alcoholic steatohepatitis liver diagnostic test for the clinical research market.
Copyright AFP 2017-2021. All rights reserved. Photos of alleged Covid-19 “vaccines” are being shared on social media with claims that the drugs are not for sale in the US, Canada, and the European Union because they are unsafe and still undergoing testing in developing countries. This is false: these products are not vaccines. They are generic forms of remdesivir, an anti-viral drug recommended for the treatment of Covid-19 and which is sold under a different name in developed markets. “Not (for) distribution in US, EU and Canada. But they shipping it to Africa? (s.i.c),” reads a Facebook post shared on September 4, 2020.